Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis

American Journal of Kidney Diseases

Volumn 31, Issue 6, 1998, Pages 1019-1027

  Joy, Melanie S ^b   Matzke, Gary R ^a   Frye, Reginald F ^b   Palevsky, Paul M ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b NONE

Author keywords

Continuous renal replacement therapy; Pharmacokinetics; Vancomycin

Indexed keywords

ACRYLONITRILE; POLY(METHYL METHACRYLATE); POLYSULFONE; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DIALYSIS MEMBRANE; DOSE CALCULATION; DRUG CLEARANCE; FEMALE; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE;

EID: 0031749303     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v31.pm9631848     Document Type: Article

References (24)

1. Conger JD: The role of continuous renal replacement therapy in the future treatment of acute renal failure. Am J Kidney Dis 28: S108-S113, 1996 (suppl 3)
2. Joy MS, Matzke GR, Armstrong DA, Marx M, Zarowitz BJ: A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 32:362-375, 1998
3. Ronco C: Continuous renal replacement therapies: Evolution towards a new era. Semin Dial 9:215-221, 1996
4. Sigler MH: Transport characteristics of the slow therapies: Implications for achieving adequacy of dialysis in acute renal failure. Adv Renal Replace Ther 4:68-80, 1997
5. Bresolle F, Kinowski JM, de la Coussaye JE, Wynn N, Eledjam JJ, Galtier M: Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet 26:457-471, 1994
6. Kroh UF, Hall TJ, Steinhauber W: Management of drug dosing in continuous renal replacement therapy. Semin Dial 9:161-165, 1996
7. Sigler MH, Manns M: Membranes and devices in continuous renal replacement therapy. Semin Dial 9:98-106, 1996
8. Kronfol NO, Lau AH, Colon-Rivera J, Libertin CL: Effect of CAVH membrane types on drug-sieving coefficients and clearances. ASAIO Trans 32:85-87, 1986
9. Relton S, Greenberg A, Palevsky PM: Dialysate and blood-flow dependence of diffusive solute clearance during CVVHD. ASAIO J38: M691-M696, 1992
10. Matzke GR: Vancomycin, in Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring (ed 3). Spokane, WA, Applied Therapeutics Inc, 1992, pp 15/1-15/31
11. Macias WL, Mueller BA, Scarim SK: Vancomycin pharmacokinetics in acute renal failure: Preservation of nonrenal clearance. Clin Pharmacol Ther 50:688-694, 1991
12. Dupuis RE, Matzke GR, Maddux FW, O'Neil MG: Vancomycin disposition during continuous arteriovenous hemofiltration. Clin Pharm 8:371-374, 1989
13. Lau AH, Kronfol NO, John E: Increased vancomycin elimination with continuous hemofiltration. ASAIO Trans 33:772-774, 1987
14. Thomson AH, Grant AC, Rodger SC, Hughes RL: Gentamicin and vancomycin removal by continuous venovenous hemofiltration. Ann Pharmacother 25:127-129, 1991
15. Bellomo R, Ernest D, Parkin G, Boyce N: Clearance of vancomycin during continuous arteriovenous hemodiafiltration. Crit Care Med 18: 181-183, 1990
16. Reetze-Bonorden P, Bohler J, Kohler C, Schollmeyer P, Keller E: Elimination of vancomycin in patients on continuous arteriovenous hemodialysis. Contrib Nephrol. 93:135-139, 1991
17. Davies SP, Azadian BS, Kox WJ, Brown EA: Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis. Nephrol Dial Transplant 7:848-854, 1992
18. Santre C, Leroy O, Simon M, Georges H, Guery B, Beuscart C, Beaucaire G: Pharmacokinetics of vancomycin during continuous hemodialfiltration. Intensive Care Med 19:347-350, 1993
19. Kronfol N, Adams L. Powell S, Lau A: Clearance of drugs during continuous arteriovenous hemodialysis (CAVHD) correlates with dialysate flow rate (Qdi). Clin Res 37:9A, 1989 (abstr)
20. Li L, Miles MV, Lakkis H, Zaritsdy AL: Vancomycin-binding characteristics in patients with serious infections. Pharmacotherapy 16:1024-1029, 1996
21. Ifediora OC, Teehan BP, Sigler MH: Solute clearance in continuous venovenous hemodialysis: A comparison of cuprophane, polyacrylonitrile, and polysulfone membranes. ASAIO J 38: M697-M701, 1992
22. Touchette MA, Patel RV, Anandan JV, Dumler F, Zarowitz BJ: Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease. Am J Kidney Dis 26:469-474, 1995
23. Welage LS, Mason NA, Hoffman EJ, Odeh RM, Dombrowski J, Patel A, Swartz RD: Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics. J Am Soc Nephrol 6:1284-1290, 1995
24. Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullins RE, Maroni BJ: Vancomycin redistribution: Dosing recommendations following high-flux hemodialysis. Kidney Int 45:232-237, 1994